PA GOODDOCTOR (01833.HK) -0.010 (-0.144%) Short selling $4.24M; Ratio 11.397% and Gohill Pharma have reached a strategic partnership regarding the Komfymed brand. This move marks a new phase in PA GOODDOCTOR's strategic expansion into the medical health device sector.Under the partnership, both parties, together with Komfymed, will drive innovative applications of recombinant collagen and related products, offering users a richer, more convenient, intelligent, and efficient suite of health management solutions.Related NewsCiti Initiates Coverage on MAO GEPING w/ Rating Buy & TP HKD130As the flagship brand under GIANT BIOGENE (02367.HK) -4.650 (-5.716%) Short selling $140.39M; Ratio 11.075% , Komfymed has focused on recombinant collagen as its core technology since its founding in 2011. The brand is dedicated to addressing skin issues such as sensitivity, dermatitis, acne, and post-cosmetic procedure care, with a strong emphasis on dermatological research and skin science care.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-23 16:25.)